Diarylquinolines target subunit c of mycobacterial ATP synthase
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The diarylquinoline R207910 (TMC207) is a promising candidate in clinical development for the treatment of tuberculosis. Though R207910-resistant mycobacteria bear mutations in ATP synthase, the compound's precise target is not known. Here we establish by genetic, biochemical and binding assays that the oligomeric subunit c (AtpE) of ATP synthase is the target of R207910. Thus targeting energy metabolism is a new, promising approach for antibacterial drug discovery.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most promising compounds clinically, the diarylquinolines, have been shown to target the F1Fo-ATP synthase and inhibit ATP synthesis (109, 111, 112).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [111]
Citations
Cites
Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country
Dye, C., Scheele, S., >Dolin, P., Pathania, V., Raviglione, M. C., & for the WHO Global Surveillance and Monitoring Project (1999) · JAMA · doi:10.1001/jama.282.7.677 · Cited by 2,947
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
Self-citationMolecular mechanisms that confer antibacterial drug resistance
Walsh, C. (2000) · Nature · doi:10.1038/35021219 · Cited by 1,578
The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol
Telenti, A., Philipp, W. J., Sreevatsan, S., Bernasconi, C., Stockbauer, K. E., Wieles, B., Musser, J. M., & Jacobs, W. R. (1997) · Nature Medicine · doi:10.1038/nm0597-567 · Cited by 472
Telenti, A., Honoré, N., Bernasconi, C., March, J., Ortega, A., Heym, B., Takiff, H. E., & Cole, S. T. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.3.719-723.1997 · Cited by 320
de Jonge, M. R., Koymans, L. H. M., Guillemont, J. E. G., Koul, A., & Andries, K. (2007) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.21376 · Cited by 124
Self-citationThe F 1 F o -ATP Synthase of Mycobacterium smegmatis Is Essential for Growth
Tran, S. L., & Cook, G. M. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.14.5023-5028.2005 · Cited by 116
Ji, B., Lefrançois, S., Robert, J., Chauffour, A., Truffot-Pernot, C., & Jarlier, V. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00052-06 · Cited by 107
Wang, R., Prince, J. T., & Marcotte, E. M. (2005) · Genome Research · doi:10.1101/gr.3994105 · Cited by 86
Junge, W., & Nelson, N. (2005) · Science · doi:10.1126/science.1112617 · Cited by 60
Cited by
Items 501–571 of 571
Bedaquiline - A Novel Promising Discovery in Multidrug-Resistant Tuberculosis
Kumar, S., Rani, S., Ch, R., Siwach, E., & Verma, P. (2013)
Biosynthetic Mechanism of the Antibiotic Capuramycin
Yan, E. (2018) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2018.360
Design of novel F-ATP synthase inhibitors of mycobacterium tuberculosis
Hotra, A. (2018) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/75829
Hughes, S. J. (2017) · TSpace (University of Toronto) · Cited by 1
Ion homeostasis in Mycobacterium smegmatis
Vercoe, M., & Blake, R. I. (2020) · Otago University Research Archive (University of Otago)
Phenotypic Screening for Drug Discovery in Tuberculosis
Delorme, V. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160721-00198
Stanovení disociačních konstant léčiv Bedaquilinu
Cyrmonová, D. (2020) · Digitální knihovna Univerzity Pardubice (Univerzity Pardubice)
Sangeeta, S. T. (2021) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/152336
Modeling the interaction of thiozonide and atphase M.tuberculosis by the method of molecular docking
Shilov, B. V., Smirnov, A. S., & Savchenko, A. Y. (2021) · Journal Biomed · doi:10.33647/2713-0428-17-3e-170-175
Let God Rule: A Study of Gen. 32:23-32
Osf, J. Y. (1972)
Segala, E. (2012) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 1
Aldrich, C. C., Wallis, R. S., Remmel, R. P., Hegde, P. V., & Stallings, C. L. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc298
Evaluating the attractiveness of the terminal oxidases as drug targets in mycobacterium abscessus
Sorayah, R. (2021) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/155733
Skerrett, S. J. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727086437.793565567
The Medical Management of Spinal Tuberculosis
Anand, K. S. S. V., & Kanna, R. M. (2022) · Springer eBooks · doi:10.1007/978-981-16-9495-0_13
Towards a New Class of Anti-Tuberculosis Drugs: Design and Synthesis of AnPRT TS Analogues
Mason, E. (2023) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.23735283
Molecular mechanism of Clofazimine resistance in tuberculosis
Sumaia, K., Afrin, S., & Shah, A. (2023) · Journal of Infectious Diseases and Immunity · doi:10.5897/jidi2020.0199
Ray, L. F. L. (2021) · theses.fr (ABES) · doi:10.70675/71d68700z0ba8z4252z9a52z7f5bb2bb44ab
Thakur, A. (2024) · African Journal of Biomedical Research · doi:10.53555/ajbr.v27i3s.3255
Diagnosis and Treatment of Mycobacterial Infections
Wang, L., Bi, L., Hu, X., & Zhang, Y. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005549
Innovative Wirkstoffe aus der antibakteriellen Forschung im Kampf gegen mikrobielle Resistenzen
Süßmuth, R. D., Kulike-Koczula, M. D., Gao, P., & Kosol, S. (2025) · Angewandte Chemie · doi:10.1002/ange.202414325
Bhardwaj, S., Gundala, R., & Roy, K. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-75457-9_5
Potential targets for the new anti-tuberculosis drug of the diarylquinoline group thiozonide
Savchenko, A. Y., & Shilov, B. V. (2025) · Drug development & registration · doi:10.33380/2305-2066-2025-14-2-2065
Mycobacterium Energy Metabolism as a Promising Target for Anti-TB Drugs
Kaur, B., Sharma, S., Chauhan, I., & Gupta, M. (2025) · Current Topics in Chemistry · doi:10.2174/0129504023342762250325065553
Nelson, K. M. (2013) · University of Minnesota Digital Conservancy (University of Minnesota)
Chen, J. (2010) · University of Birmingham Institutional Research Archive (University of Birmingham) · Cited by 1
Wang, M.-G., Wu, S.-Q., & He, J.-Q. (2021) · Figshare · doi:10.6084/m9.figshare.16639663
Harrison, S. H. (2024) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Akwani, W. C., Rakowska, P. D., Gilmore, I., Chambers, M., McMahon, G., & Hingley‐Wilson, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.16.589735
Evaluation of antimicrobial resistance in bacterial strains isolated from Antarctica
Chavarro‐Mesa, E., Labrador, C. R., Serna, J., Taborda, N., & Valiente-Puche, M. (2025) · LACCEI International Multi-Conference for Engineering, Education and Technology (LACCEI) · doi:10.18687/laccei2025.1.1.1890
Bedaquiline – Shot in the Arm for Shorter Drug-resistant Tuberculosis Regimens
Sridhar, R. (2026) · Journal of Association of Pulmonologist of Tamil Nadu · doi:10.4103/japt.japt_1_26
Menaquinone depletion resensitises bedaquiline-resistant tuberculosisPreprint
Wetzel, J., Dallow, J., Davis, E., Pearson, W. H., Daems, S., Govaerts, M., Hereijgers, J., Sprangers, J., Truebody, B. E., Maes, V., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.10.702511
Self-citationIssahaku, A. R., Noreljaleel, A. E. M., Murray, Z., Schutte‐Smith, M., & Wilhelm, A. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10488-z
Mycobacterium tuberculosis as a model system
Barnard, E., Elgrail, M. M., Fay, A., Ozakman, Y., & Glickman, M. S. (2026) · Journal of Bacteriology · doi:10.1128/jb.00609-25
Drug discovery against mycobacteria: The success and challenges
Maindolia, R., Pramanik, S., Mukhopadhyay, A., Ghosh, A., Malik, P., Ali, J., Rana, P., Chopra, S., & Dasgupta, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36518-8.00002-3
Wen, S., Li, H., Shi, Y., Wei, R., Ge, F., Pang, Y., & Liu, Y. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s580421
Belon, C. (2015) · theses.fr (ABES) · doi:10.70675/192cf3d7z5208z4e1bz962fz5ded2494b202 · Cited by 1
Gutiérrez, A. V. (2019) · theses.fr (ABES) · doi:10.70675/3a2fa1dbz125cz41f4z9b09zd325102dda0d
Impact des antibiotiques sur la réponse des macrophages humains : l'exemple de la bédaquiline
Giraud-Gatineau, A. (2019) · theses.fr (ABES) · doi:10.70675/e7540acaz0a22z4dcfz8d5azdf6f3232c4b4
Mécanismes de régulation impliqués dans la résistance aux antibiotiques chez Mycobacterium abscessus
Richard, M. (2019) · theses.fr (ABES) · doi:10.70675/9a114617zb1ddz4e36z8ebfzb82e0872005c
Implication des enzymes lipolytiques dans la virulence et la survie mycobactérienne
Santucci, P. (2018) · theses.fr (ABES) · doi:10.70675/b1318398z3b3ez47caza99cz49045a043924
Liu, C., Zhang, L., Wang, Z., Li, X., Wang, B., & Lu, Y. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.20.726459
Détermination de la cible moléculaire et du mode d'action de la tomatidine et dérivés
Boulet, M. L. (2017) · Knowledge UdeS (Institutional Deposit of the University of Sherbrooke)
Caractérisation de l'activité de la tomatidine et de ses dérivés sur l'ATP synthétase
Isabelle, C. (2018) · Knowledge UdeS (Institutional Deposit of the University of Sherbrooke)
Sahile, H. A., Awasthi, B. P., Olsen, J. E., Afshar, H., Kim, S.-W., Amrom, I., Nikjo, Z., Rankine-Wilson, L., Law, W. W. H., Vimalanathan, S., et al. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6c00420
Sakaria, R. A., Modi, B., Nayudu, S. A., Chattopadhyay, P. K., Singh, D. R., & Koria, D. B. (2026) · Genetics and Molecular Research · doi:10.4238/pss4rn55
Clinical Development of Antibacterial Drugs: Recent Progress and Future Outlook
Kathayat, D., Vidovszky, A., Khan, Y., Denk, A., Paudel, A., Verma, A., Helmy, Y. A., & Rajashekara, G. (2026) · Antibiotics · doi:10.3390/antibiotics15100993
Kibiloski, A. P., Dechow, S. J., Abdalla, B. J., Murdoch, H. M., Tischler, A. D., & Abramovitch, R. B. (2026) · PLoS Genetics · doi:10.1371/journal.pgen.1012331
Jiang, Y., Mo, S.-Q., Zhao, Y.-Y., Guo, X.-Y., Li, Y.-H., Xia, K.-Q., Peng, X.-T., Li, C.-C., Zhao, Y., Wang, X.-T., et al. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-05251-4
Roy, A., Sau, S., Agnivesh, P. K., Parida, K. K., & Kalia, N. P. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119984
BindingDB Entry 50022407: Targeting polyketide synthase 13 for the treatment of tuberculosis.
BindingDB (2025) · UC San Diego · doi:10.7270/q22230gb
BindingDB (2024) · UC San Diego · doi:10.7270/q2sb4b19
BindingDB Entry 50010835: Molecule Property Analyses of Active Compounds for
BindingDB (2021) · UC San Diego · doi:10.7270/q21z480d
Opportunities and Challenges in Clinical and Preclinical Drug Development for Mycobacterium marinum
Jing, Q.-Q., Wang, W., Zhang, Q., Xu, T., Wei, M., & Shao, C. (2026) · Medicinal Research Reviews · doi:10.1002/med.70126
Metadata
- Authors
- Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., Ristic, Z., Lill, H., Dorange, I., Guillemont, J., Bald, D., & Andries, K.
- Affiliations
- Johnson & Johnson (United States) (US)
- Vrije Universiteit Amsterdam (NL)
- Johnson & Johnson (France) (FR)
- Corresponding author
- Koul, Anil
- Venue
- Nature Chemical Biology
- Published
- 2007-05-13
- Volume
- 3
- Issue
- 6
- Pages
- 323-324
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2093364655
- Cited by
- 547
- References
- 11
- Citations by year
- 2026: 17 · 2025: 24 · 2024: 27 · 2023: 27 · 2022: 40 · 2021: 50 · 2020: 31 · 2019: 40 · 2018: 36 · 2017: 40 · 2016: 23 · 2015: 33 · 2014: 26 · 2013: 31 · 2012: 22
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- VU Research Portal (publishedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- diarylquinolines, bedaquiline, subunit c, atpE, tuberculosis, drug target identification, drug resistance, energy metabolism, antibiotic discovery
- MeSH terms
- Antitubercular Agents, Bacterial Proteins, Binding Sites, Kinetics, Quinolines, Electrophoresis, Gel, Two-Dimensional, Mycobacterium smegmatis, Protein Subunits, ATP Synthetase Complexes, Bacterial Proton-Translocating ATPases, Diarylquinolines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.